Personalis presents ultrasensitive cancer relapse detection data at ASCO
Personalis (NASDAQ:PSNL) unveiled comprehensive clinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, establishing the diagnostic capabilities of its ultrasensitive minimal residual disease (MRD) detection platform.










